Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Syneos Health, Inc. (SYNH)
Sector: Healthcare; Industry: Diagnostics & Research

Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including medication adherence, communications solutions, and consulting services. Syneos Health, Inc. has a strategic agreement with Daiichi Sankyo, Inc. for the development of Daiichi Sankyo'S Adc oncology pipeline.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-04-15 Meggs Jason M. Chief Financial Officer Sell 6,000 $84.00 $504,000 No
2021-04-15 KEEFE MICHELLE Pres., Commercial Solutions Sell 2,736 $82.00 $224,352 No
2021-04-09 Macdonald Alistair Chief Executive Officer Sell 14,039 $80.00 $1,123,120 No
2021-04-01 Macdonald Alistair Chief Executive Officer Sell 17,398 $77.61 $1,350,190 Yes
2021-03-31 KEEFE MICHELLE Pres., Commercial Solutions Sell 2,000 $78.00 $156,000 No
2021-03-29 Olefson Jonathan General Counsel & Corp Secty Sell 4,000 $77.00 $308,000 No
2021-03-29 Harty Linda S Director Sell 7,310 $76.49 $559,142 No
2021-03-03 Maldonado John L. Director Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 Allen Tom Director Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 4,654,046 $74.17 $345,213,862 No
2021-03-03 THOMAS H. LEE ADVISORS, LLC 10%-Owner, Director Sell 3,995,954 $74.18 $296,399,888 No
2021-03-03 THOMAS H. LEE ADVISORS, LLC 10%-Owner, Director Sell 3,995,954 $74.18 $296,399,888 No
2021-03-03 Kralowetz Donna Hildebrand SVP, Chief Accounting Officer Sell 248 $74.64 $18,511 No
2021-02-16 Kralowetz Donna Hildebrand SVP, Chief Accounting Officer Sell 362 $81.00 $29,322 No
2021-02-02 Macdonald Alistair Chief Executive Officer Sell 64,497 $75.71 $4,883,247 No
2021-02-01 COLVIN PAUL Pres., Clinical Solutions Sell 8,486 $74.82 $634,923 No
2021-01-25 Olefson Jonathan General Counsel & Corp Secty Sell 5,336 $75.68 $403,828 No
2021-01-25 KEEFE MICHELLE Pres., Commercial Solutions Sell 4,000 $75.68 $302,720 No
2021-01-06 Meggs Jason M. Chief Financial Officer Sell 5,552 $72.00 $399,744 No
2020-12-23 Macdonald Alistair Chief Executive Officer Sell 1,500 $70.12 $105,176 No
2020-12-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 3,228,241 $61.28 $197,826,608 No
2020-12-03 Allen Tom Director Sell 3,228,241 $61.28 $197,826,608 No
2020-12-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 3,228,241 $61.28 $197,826,608 No
2020-12-03 ADVENT INTERNATIONAL CORP/MA 10%-Owner Sell 3,228,241 $61.28 $197,826,608 No
2020-12-03 Maldonado John L. Director Sell 3,228,241 $61.28 $197,826,608 No

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.